Responder HF

INVESTIGATORS	• **Viviana Navas, MD- Primary investigator** • **Mazen Albaghdadi, MD- Sub-Investigator** • **Adam Frank, MD- Sub Investigator** • **Robert Cubeddu, MD – Sub-Investigator**
Trial Objective	• **The primary objective of this clinical trial is to further evaluate the clinical efficacy of the Corvia Atrial Shunt in symptomatic heart failure patients with a left ventricular ejection fraction (LVEF) ≥ 40%, and elevated left sided filling pressures despite standard Guideline-Directed Medical Therapy (GDMT); and to confirm the treatment effect observed in the responder group of the REDUCE LAP-HF Randomized Trial II.**
Randomization	• **1:1 randomization (Device vs. Sham)**
Key Inclusion	• **Chronic symptomatic Heart failure** • **Ongoing stable GDMT HF management** • **Age≥ 40 years old**
Key Exclusion	• **Advance heart failure defined as:** a. ACC/AHA/ESC Stage D heart failure, Non-ambulatory NYHA Class IV HF b. Cardiac index < 2.0 L/min/m2 c. Inotropic infusion (continuous or intermittent) for EF < 40% within the past 6 months d. Patient is on the cardiac transplant waiting list • **Inability to preform 6 minute walk test(distance<50m) or 6MWT>600m** • **Participants with existing or surgically closed (with a patch) atrial septal defects** • **COPD, requiring continuous home oxygen**